Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib Combined with Bevacizumab and Pemetrexed in Advanced NSCLC with EGFRm and Leptomeningeal Metastasis
NCT06643000Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Dec 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM), sponsored by Henan Cancer Hospital. Primary endpoint: Overall Survival. Started Dec 2024; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06643000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643000.